Home › Funds › Soleus Capital Management, L.P. › PHVS

Soleus Capital Management, L.P. position in PHVS

PHARVARIS N V · Health Care

Soleus Capital Management, L.P. reported holding 730,907 shares of PHVS (PHARVARIS N V) in its Q2 2026 13F filing — a position valued at US$25.3M, representing 0.87% of its reported portfolio and ranking #32 among its reported holdings. Soleus Capital Management, L.P. has disclosed PHVS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)730.91K sh
Reported value held$25.27M
Portfolio Weight0.87%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s PHVS position evolved

Soleus Capital Management, L.P. first disclosed a stake in PHVS in Q3 2023 at 343,975 shares (US$7.2M). The position peaked in Q2 2026 at 730,907 shares, worth US$25.3M. Across 12 filings, Soleus Capital Management, L.P. increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 730,907 shares valued at US$25.3M — an increase of 28,855 shares quarter over quarter.. Notable position changes include a 37% trim in Q4 2023 (shares fell 33% over the following quarter), a 85% increase in Q1 2024, a 50% increase in Q3 2024.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 343.98K $7.18M New
Q4 2023 217.40K $6.10M Reduce
Q1 2024 401.90K $9.29M Add
Q2 2024 399.43K $7.51M Reduce
Q3 2024 598.17K $11.08M Add
Q4 2024 814.65K $15.62M Add
Q1 2025 814.65K $12.79M Hold
Q2 2025 732.97K $12.90M Reduce
Q3 2025 647.05K $16.14M Reduce
Q4 2025 702.05K $19.48M Add
Q1 2026 702.05K $19.83M Hold
Q2 2026 730.91K $25.27M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PHVS and 13F data

PHVS (PHARVARIS N V) is a Health Care company. 49 other funds we track also report a position in PHVS — the largest reported positions include GENERAL ATLANTIC, L.P. (US$226.5M), Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PHVS

All PHVS fund holders →

FAQ

How long has Soleus Capital Management, L.P. held PHVS?

Soleus Capital Management, L.P. has disclosed PHVS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in PHVS?

As of Q2 2026, Soleus Capital Management, L.P. holds 730.91K shares of PHVS (PHARVARIS N V), valued at $25.27M, representing 0.87% of its reported portfolio and ranking #32.

Has Soleus Capital Management, L.P. been buying or selling PHVS?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. increased its position in PHVS. The position peaked in Q2 2026 at 730.91K shares.

Which other funds hold PHVS?

Other major institutional holders of PHVS include GENERAL ATLANTIC, L.P., Foresite Capital Management IV, LLC, venBio Partners LLC, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.